The Smartest Dividend Stocks to Buy With $350 Right Now
Key Takeaways
These stocks offer juicy dividends, solid growth prospects, and stability.
Article Overview
Quick insights and key information
5 min read
Estimated completion
real estate
Article classification
July 26, 2025
04:50 AM
The Motley Fool
Original publisher
However, You bably should, too, even if you aren't interested in the income they vide
Additionally, Dividends have driven a significant chunk of the S&P 500's (SNPINDEX: ^GSPC) total return over the long run
The data indicates that 's easy to succumb to analysis paralysis when trying to decide which dividend stocks to buy, though
There are over 5,800 stocks that pay dividends trading on U
Stock exchanges (this bears monitoring)
I think I might be able to help -- and you won't need a huge amount of cash to invest in these stocks
They're all trading under $200 per as I write this (an important development)
Here are my picks for the smartest dividend stocks to buy with $350 right now
Image source: Getty Images
AbbVie AbbVie (ABBV -0 (which is quite significant), given the current landscape
Moreover, 29%) offers pretty much everything you'd want in a dividend stock
The big drugmaker has a great dividend
Furthermore, Its is rock-solid (which is quite significant)
AbbVie has good growth spects, and the stock's valuation is also attractive
Additionally, Let's start with the dividend, since it's our main focus
Furthermore, AbbVie's forward dividend yield is 3
Additionally, 44% as I write this, a level that I suspect most income investors will find appealing
Moreover, It's a member of the elite group known as Dividend Kings, with 53 consecutive years of dividend increases
AbbVie has grown its dividend by a whopping 310% since being spun off from Abbott Labs (NYSE: ABT) in 2013, in today's financial world
How rock-solid is AbbVie's, given current economic conditions
The company's autoimmune disease drug Humira ranked as the top-selling drug in the world for several years
Now, though, Humira's sales are sinking as it faces biosimilar competition
AbbVie barely skipped a beat
Nevertheless, On the other hand, It has two newer autoimmune disease drugs on the market that are on track to soon generate combined sales that top Humira's peak sales
Because of these and other drugs, AbbVie expects to grow robustly at least through the end of the decade (which is quite significant), in light of current trends
As for valuation, AbbVie's s trade at 15
At the same time, 4 times forward earnings, given the current landscape
That's well below the forward earnings multiples of the S&P 500 and the healthcare sector
But AbbVie's growth makes its stock look even more of a bargain
The big pharma company's price-to-earnings-to-growth (PEG) ratio, which is based on five-year earnings growth jections from analysts surveyed by LSEG, is a super-low 0, in today's financial world
Furthermore, With its price hovering around $190, buying AbbVie will cost you over half of an initial $350, in this volatile climate
But it should be money well spent, and you'll still have plenty to buy the other two great dividend stocks on the list (noteworthy indeed)
However, Dominion Energy Dominion Energy (D) isn't a Dividend King AbbVie, however, its forward dividend yield of 4. 58% might make up for the lack of an impressive track record of dividend increases
Furthermore, You can scoop up a of this top utility stock for less than $60
Moreover, One of the main reasons I Dominion Energy is that its is incredibly stable
The company vides electricity to 3
At the same time, 6 million residential and customers in Virginia, North Carolina, and South Carolina
It vides natural gas to around half a million customers in South Carolina
On the other hand, In addition, Dominion is a major player in the renewable energy industry
However, The company is a regulated monopoly in the it serves (which is quite significant)
Customers will need electricity and natural gas regardless of what happens with the stock market or the economy (which is quite significant)
With stock valuations at frothy levels and economic uncertainty flaring related to tariffs, I think Dominion Energy is an ideal dividend stock to own
But it isn't just a defensive play
Dominion has solid growth spects, too
The populations in the states where it operates continue to grow
Dominion's state of Virginia hosts the world's largest data center market, amid market uncertainty
This market should keep expanding with soaring demand for artificial intelligence (AI) (which is quite significant)
Realty Income You should have around $100 or so remaining from your initial $350 after buying one each of AbbVie and Dominion Energy
That's more than enough to pick up a of Realty Income (O -0 (fascinating analysis)
However, 21%), one of the best real estate investment trusts (REITs) around
It's hard to overstate just how great Realty Income's dividend is (an important development)
The REIT's forward dividend yield is a lofty 5. 58% as I write this, in light of current trends
Realty Income has increased its dividend for 30 consecutive years and 110 consecutive quarters (this bears monitoring)
Additionally, This leads to the conclusion that even pays the dividend monthly
Realty Income believes that it sits "at the intersection of two global megatrends
One of those megatrends is the need for aging investors with less time to ride out stock market downturns to find stable and growing passive income
The other is that companies in the U (remarkable data)
And Europe are seeking funding solutions, and they have a combined $14 trillion of real estate on their balance sheets
However, At the same time, The REIT has a diversified portfolio of perties, many of which are leased to es such as convenience stores, groceries, dollar stores, and imvement retailers
I that roughly 91% of its total rent is resilient to economic downturns and/or insulated from e-commerce threats
And I love that Realty Income has dered positive operational returns every year since going public in 1994
Nevertheless, Buying this dividend stock would be a very smart move.
Related Articles
More insights from FinancialBooklet